Search clinical trials for: palifermin

Total 52 results

Brett King
Swedish Orphan Biovitrum

Terminated

Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis

Stevens-Johnson Syndrome | Toxic Epidermal Necrolysis

United States
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults

HIV Infections

United States
St. Jude Children's Research Hospital

Completed

Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Hematopoietic Stem Cell Transplantation | Oral Mucositis

United States
Amgen

Completed

A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer

Head and Neck Cancer
Swedish Orphan Biovitrum

Completed

A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma

Multiple Myeloma

Germany
The Catholic University of Korea
BLNH

Unknown

Palifermin for Patients Receiving Hematopoietic Stem Cell Transplantation

Mucositis
Swedish Orphan Biovitrum
Amgen

Withdrawn

A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy

Head and Neck Cancer
Swedish Orphan Biovitrum
Amgen

Completed

Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support

Lymphoma | Leukemia | Myeloma
Swedish Orphan Biovitrum

Completed

PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation

Multiple Myeloma | Non-Hodgkin's Lymphoma
Swedish Orphan Biovitrum
Amgen

Completed

A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy

Head and Neck Cancer | Mucositis
Swedish Orphan Biovitrum

Completed

A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT

Leukemia

United States
Amgen

Completed

A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer

Colon Cancer
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Terminated

Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer

Pain | Head and Neck Cancer | Mucositis | Radiation Toxicity

United States, Canada
Cambridge University Hospitals NHS Foundation Trust

Terminated

Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis (CAM-THY)

Multiple Sclerosis

United Kingdom
Swedish Orphan Biovitrum

Completed

Palifermin DDI (Drug Drug Interaction)

Healthy Volunteers
Swedish Orphan Biovitrum

Completed

Study to Characterize the Effect of Heparin on Palifermin Activity

Oral Mucositis

United States
McGill University Health Centre/Research Institute...

Terminated

Effect of Palifermin on Skin Tumors in Patients Undergoing Bone Marrow Transplantation (Palifermin)

Skin Rash

Canada
Swedish Orphan Biovitrum
Amgen

Completed

Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer

Head and Neck Cancer | Mucositis | Stomatitis | Solid Tumors | Squamous Cell Carcinoma
European Society for Blood and Marrow Transplantation
Amgen

Withdrawn

Palifermin After Haploidentical PBSCT (KGF Haplo Allo)

Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Acute Leukaemia | Non-Hodgkin's Lymphoma or Hodgkin's Disease | Osteomyelofibrosis

Germany
University Hospital Southampton NHS Foundation...

Completed

A Study to Assess Safety and Efficacy of a Novel Treatment, Keratinocyte Growth Factor (KGF), in Asthmatic Patients

Bronchial Asthma

United Kingdom
Swedish Orphan Biovitrum
Amgen

Completed

Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer | Lung Cancer | Dysphagia
Martin, Paul
National Cancer Institute (NCI)

Completed

Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer

Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Acute Leukemia | Myelodysplastic Syndrome

United States
Children's Oncology Group
National Cancer Institute (NCI)

Withdrawn

Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant

Malignant Neoplasm | Gastrointestinal Mucositis
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

Multiple Myeloma | Mucositis

United States
National Institute of Allergy and Infectious Diseases...

Unknown

Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency (LVXSCID-OC)

X-Linked Combined Immunodeficiency Diseases

United States
Sherif S. Farag

Terminated

Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplasia

United States
National Institute of Allergy and Infectious Diseases...

Enrolling by invitation

Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease

Chronic Granulomatous Disease (CGD) | X-Linked Chronic Granulomatous Disease

United States
Memorial Sloan Kettering Cancer Center
Swedish Orphan Biovitrum

Active, not recruiting

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Leukemia | Multiple Myeloma | Non-Hodgkin's Lymphoma | Myelodysplastic Syndrome

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

X-linked Severe Combined Immunodeficiency (XSCID)

United States
M.D. Anderson Cancer Center

Completed

High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease

Lymphoma

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Radiation Toxicity | Oral Complications | Drug/Agent Toxicity by Tissue/Organ

United States
M.D. Anderson Cancer Center

Completed

Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma

Sarcoma | Oral Mucositis

United States
Daiichi Sankyo

Recruiting

A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

COPD Exacerbation Acute

China
Swedish Orphan Biovitrum
Amgen

Completed

Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)

Lymphoma | Leukemia | Cancer
Memorial Sloan Kettering Cancer Center

Completed

Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia | Advanced Myelodysplastic Syndromes

United States
Swedish Orphan Biovitrum
Amgen

Completed

Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation

Hematologic Malignancies | Graft Versus Host Disease
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer

Lymphoma | Leukemia | Oral Complications

United States
M.D. Anderson Cancer Center

Completed

Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies

Lymphoma | Leukemia | Myeloma

United States
Columbia University

Terminated

Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB) (RDEB)

Epidermolysis Bullosa

United States
M.D. Anderson Cancer Center

Completed

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Myeloma

United States
M.D. Anderson Cancer Center

Completed

Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies

Lymphoma

United States
Montefiore Medical Center
Nationwide Children's Hospital; Children's Hospital Los Angeles

Terminated

A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors

Solid Tumor | Allogeneic Hematopoietic Stem Cell Transplantation | Neuroepithelial Tumor

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center

Terminated

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

T-cell Non-Hodgkin Lymphoma

United States
M.D. Anderson Cancer Center

Withdrawn

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

Myeloma
University College, London

Active, not recruiting

Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (UKALL14)

Leukemia | Mucositis | Oral Complications

United Kingdom
M.D. Anderson Cancer Center

Withdrawn

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

Lymphoma
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma

Plasma Cell Myeloma | Plasma Cell Leukemia in Remission

United States

3

Subscribe